top of page
Expertise
VIA Performance
78%
56%
17%
22%
By Therapeutic Area
KOR
JPN
5%
11%
Phase II
Phase III
Ophthalmology
17%
6%
EU
5%
11%
11%
By Country
Phase IV
Gastroenterology
28%
Cardiovasular
OS/PMS
Hematology
Medical Device
ETC.
By Phase
Endocrinology
11%
Allergology
5%
Pulmonology
6%
6%
ETC.
5%
eConsent Performance
43%
15%
By Therapeutic Area
KOR
JPN
14%
14%
Phase I
Phase III
14%
43%
Ophthalmology
Cardiovascular
57%
15%
14%
By Phase
Neurology
OS/PMS
Food & supplementary
IIT
Allergology
43%
ETC.
By Country
14%
14%
2024.03 Now
Partnerships
Spero's business partners range from local and overseas clinical trial sponsors, pharmaceutical and medical device companies, to CROs and clinical research sites and centers
Key fields of cooperation
-
Clinical development operation (CRO service)
-
Patient recruitment service support
-
DCT solution operation support
PMS
3%
Phase IV
3%
Achievement
Spero started patient recruitment service in 2021 and has been accumulating achievements in various CRO service areas since it expanded its business to DCT in 2022.
Therapeutic Area & Phase
Experienced Staffs and Potential expertise
Spero is enhancing its expertise and operational efficiency for the successful execution of clinical trials
45%
Ophthalmology
Gastroenterology
Endocrinology
Cardiovascular
Pulmonology
Hematology
6%
6%
10%
6%
13%
29%
By Therapeutic area
By Phase
Others
Medical Device
IIT
OS
Phase I
Phase III
Phase II
3%
3%
13%
6%
13%
Neurology
Infectious disease
Others
13%
6%
10%
10%
Clinical Operation
Full Support Service
Spero supports all phases of clinical trials, and prioritizes customer requirements, and the safety of clinical trials
16%
16%
28%
31%
5%
5%
Statistics
Data Management
Medical Writing
Site Management
Project Management
Site Startup
By Operation service
*Site Management : VIA/cubeRBQM service included.
3%
3%
PMS
Phase IV
bottom of page